Adamis Wins FDA Approval for EpiPen Rival

Jun 16, 2017


California-based Adamis Pharmaceuticals has received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions -- a rival to Mylan's EpiPen.

Adamis has not set the price for its Symjepi product yet, but plans to position the product as a lower cost alternative to EpiPen.

After a pricing debate last summer, Mylan released an authorized generic version of the EpiPen for $300 for a two-pack. CVS made an authorized generic for Impax Labs' Adrenaclick IPXL available at about $100 for a two-pack early this year.

The Adamis product should launch by the middle of this summer. The approval sent Adamis shares up more than 50 percent.

Read the Reuters press release



Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments